Solifenacin

Solifenacin

SCHEMBL1735698

O=C(O[C@@H]1CN2CCC1CC2)N1CCc2ccccc2C1c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM2CHRM3

The experimentally established mechanism targets of Solifenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CHRM3 known ✓ P20309 8/20 1.00
CHRM2 known ✓ P08172 2/20 1.00
CHRM1 P11229 2/20 1.00
KCNH2 Q12809 2/20 1.00
CACNA1F O60840 1/20 1.00
CHRM4 P08173 1/20 1.00
CHRM5 P08912 1/20 1.00
KCNE1 P15382 1/20 1.00
KCNQ1 P51787 1/20 1.00
CACNA1D Q01668 1/20 1.00
CACNA1S Q13698 1/20 1.00
CACNA1C Q13936 1/20 1.00
SCN5A Q14524 1/20 1.00
KCND3 Q9UK17 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Solifenacin SCHEMBL29850238 1.00 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2CACNA1F
Solifenacin SCHEMBL1736633 1.00 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2CACNA1F
Solifenacin SCHEMBL9971260 1.00 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2CACNA1F
Solifenacin SCHEMBL1735770 1.00 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2CACNA1F
Solifenacin SCHEMBL1566459 1.00 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2CACNA1F
Solifenacin SCHEMBL13298567 1.00 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2CACNA1F
Solifenacin SCHEMBL1478523 1.00 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2CACNA1F
Solifenacin SCHEMBL12046704 1.00 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2CACNA1F
Solifenacin SCHEMBL1566144 1.00 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2CACNA1F
Solifenacin SCHEMBL1566240 1.00 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2CACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140228575-A1 Process for the Preparation of Solifenacin and Salts Thereof ISOCHEM (FR) 2014-08-14 US claimed
EP-3067353-B1 A PROCESS FOR THE PREPARATION OF SOLIFENACIN SALTS AND THEIR INCLUSION INTO PHARMACEUTICAL DOSAGE FORMS KRKA D D NOVO MESTO (SI) 2017-11-22 EP disclosed
EP-3067353-A1 A PROCESS FOR THE PREPARATION OF SOLIFENACIN SALTS AND THEIR INCLUSION INTO PHARMACEUTICAL DOSAGE FORMS KRKA, D.D., Novo Mesto (SI) 2016-09-14 EP disclosed
US-20140228575-A1 Process for the Preparation of Solifenacin and Salts Thereof ISOCHEM (FR) 2014-08-14 US disclosed
US-20140228575-A1 Process for the Preparation of Solifenacin and Salts Thereof ISOCHEM (FR) 2014-08-14 US disclosed
EP-2305676-B1 Synthesis of solifenacin monosuccinate ASTELLAS PHARMA INC (JP) 2012-10-17 EP disclosed
EP-2094693-B1 A METHOD FOR THE PREPARATION OF SOLIFENACIN ZENTIVA KS (CZ) 2011-11-16 EP disclosed
US-20110264760-A1 METHOD AND APPARATUS PROVIDING FOR OUTPUT OF A CONTENT PACKAGE BY AN APPLICATION BASED AT LEAST IN PART ON A CONTENT TYPE SELECTION AND ONE OR MORE CONTEXTUAL CHARACTERISTICS NOKIA CORPORATION 2011-10-27 US disclosed
US-20100145055-A1 METHOD FOR THE PREPARATION OF SOLIFENACIN ZENTIVA K.S. (CZ) 2010-06-10 US disclosed
WO-2010012459-A2 A PROCESS FOR THE PREPARATION OF SOLIFENACIN SALTS AND THEIR INCLUSION INTO PHARMACEUTICAL DOSAGE FORMS KRKA, D.D., NOVO MESTO (SI) 2010-02-04 WO disclosed
US-20090326230-A1 PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS DR. REDDY'S LABORATORIES LTD. (IN) 2009-12-31 US disclosed
US-20090326230-A1 PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS DR. REDDY'S LABORATORIES LTD. (IN) 2009-12-31 US disclosed
US-20090326230-A1 PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS DR. REDDY'S LABORATORIES LTD. (IN) 2009-12-31 US disclosed
WO-2008011462-A2 PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS DR. REDDY'S LABORATORIES LTD. (IN) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145055-A1 METHOD FOR THE PREPARATION OF SOLIFENACIN CHRNA3, CHRM3, CHRNA1 CHRM3 2/4885CHRM2 20/4885CHRM1 24/4885
US-20090326230-A1 PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS OPRL1, ADRA1A, OPRK1 CHRM3 11/4885CHRM2 49/4885CHRM1 12/4885
US-20140228575-A1 Process for the Preparation of Solifenacin and Salts Thereof NEU3, NEU4, ADRB3 CHRM3 9/4885CHRM2 49/4885CHRM1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.